Page 2 - Param Desai News Today

Get latest articles and stories on World at LatestLY. The Indian-American diaspora is gearing up to commemorate the consecration ceremony of the Ram Mandir in Ayodhya, with plans to hold car rallies in the US to celebrate the occasion. World News | Huge Car Rally Planned in California to Celebrate Ram Mandir Consecration in Ayodhya.

After the separation, the India and GCC entities will operate under dedicated management teams

“We believe that Ciplas Pithampur facility was inspected in February and post that, they got an OAI in August and post that, it has escalated to a warning letter. We believe that it is unlikely that this will escalate further to import alerts, though this may take some time to resolve.”

A strong performance in the July-September quarter of 2023-24 (Q2FY24), an upward revision in the margin guidance and sustained momentum in US sales has helped the stock of pharmaceutical major Cipla gain about 2 per cent over the last two trading sessions. The brokerages have upgraded the earnings estimates for this financial year (FY24) by 6-9 per cent to factor in the improved margin guidance and sales in the US market. Led by the US market, which rose by 31 per cent, the company posted a 16 ...

Even as the broader markets were under pressure, the stock of Torrent Pharmaceuticals was down 1.05 per cent on October 26. This was on expectation that steady sales growth momentum in core markets such as India and Brazil and recovery in the US market coupled with margin expansion will drive strong earnings growth over the next couple of years. Brokerages are working with the net profit growth of 28-34 per cent annually over the FY23-25 period.

Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains coming in the last three months. The stock is riding on multiple triggers given its investments in the production-linked incentive or PLI scheme, biosimilars, injectables and vaccines, which should drive revenues and profits over the medium term. Better than expected performance after the June quarter resul...

Torrent Pharmaceuticals (TRP IN) - Param Desai - Research Analyst, Prabhudas Lilladher Pvt Ltd.

The company’s R&D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18

Apollo’s mainstay hospitals business saw 13% growth. The other segments, Apollo Health and Lifestyle Ltd (AHLL) and Apollo HealthCo continued to show improvement.

Torrent Pharmaceuticals (TRP IN) - Param Desai - Research Analyst, Prabhudas Lilladher Pvt Ltd Rating: BUY | CMP: Rs2,055 | TP: Rs2,250 Q1FY24 Result Update - Margins to sustain Quick...